BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 24469037)

  • 21. Acetylation changes at lysine 5 of histone H4 associated with lytic gene promoters during reactivation of Kaposi's sarcoma-associated herpesvirus.
    Hwang LR; Cha S; Jong JE; Jang JH; Seo T
    Acta Virol; 2014; 58(3):282-6. PubMed ID: 25283865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Kaposi's Sarcoma-Associated Herpesvirus ORF50 Protein Represses Cellular MDM2 Expression via Suppressing the Sp1- and p53-Mediated Transactivation.
    Lin CI; Wang SS; Hung CH; Chang PJ; Chen LW
    Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955808
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Kaposi's Sarcoma-Associated Herpesvirus Reactivation by Targeting of a dCas9-Based Transcription Activator to the ORF50 Promoter.
    Elbasani E; Falasco F; Gramolelli S; Nurminen V; Günther T; Weltner J; Balboa D; Grundhoff A; Otonkoski T; Ojala PM
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32867368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential regulation of the overlapping Kaposi's sarcoma-associated herpesvirus vGCR (orf74) and LANA (orf73) promoters.
    Jeong J; Papin J; Dittmer D
    J Virol; 2001 Feb; 75(4):1798-807. PubMed ID: 11160678
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological Features of Kaposi's Sarcoma-Associated Herpesvirus Infection.
    Katano H
    Adv Exp Med Biol; 2018; 1045():357-376. PubMed ID: 29896675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kaposi's sarcoma-associated herpesvirus vIRF2 protein utilizes an IFN-dependent pathway to regulate viral early gene expression.
    Koch S; Damas M; Freise A; Hage E; Dhingra A; Rückert J; Gallo A; Kremmer E; Tegge W; Brönstrup M; Brune W; Schulz TF
    PLoS Pathog; 2019 May; 15(5):e1007743. PubMed ID: 31059555
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting Kaposi's Sarcoma-Associated Herpesvirus ORF21 Tyrosine Kinase and Viral Lytic Reactivation by Tyrosine Kinase Inhibitors Approved for Clinical Use.
    Beauclair G; Naimo E; Dubich T; Rückert J; Koch S; Dhingra A; Wirth D; Schulz TF
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31826996
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Expression and Nuclear Retention Element of Polyadenylated Nuclear RNA Is Not Required for Productive Lytic Replication of Kaposi's Sarcoma-Associated Herpesvirus.
    Gutierrez IV; Dayton J; Harger S; Rossetto CC
    J Virol; 2021 Jun; 95(13):e0009621. PubMed ID: 33853955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kaposi's Sarcoma-Associated Herpesvirus Viral Interleukin-6 Signaling Upregulates Integrin β3 Levels and Is Dependent on STAT3.
    Rivera-Soto R; Dissinger NJ; Damania B
    J Virol; 2020 Feb; 94(5):. PubMed ID: 31801855
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Kang SK; Kang YH; Yoo SM; Park C; Kim HS; Lee MS
    J Virol; 2021 Jul; 95(16):e0079921. PubMed ID: 34105998
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kaposi's sarcoma-associated herpesvirus LANA2 is a B-cell-specific latent viral protein that inhibits p53.
    Rivas C; Thlick AE; Parravicini C; Moore PS; Chang Y
    J Virol; 2001 Jan; 75(1):429-38. PubMed ID: 11119611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nutlin-3 induces apoptosis, disrupts viral latency and inhibits expression of angiopoietin-2 in Kaposi sarcoma tumor cells.
    Ye F; Lattif AA; Xie J; Weinberg A; Gao S
    Cell Cycle; 2012 Apr; 11(7):1393-9. PubMed ID: 22421142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p53 inhibition by the LANA protein of KSHV protects against cell death.
    Friborg J; Kong W; Hottiger MO; Nabel GJ
    Nature; 1999 Dec 23-30; 402(6764):889-94. PubMed ID: 10622254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Kaposi's Sarcoma-Associated Herpesvirus ORF34 Protein Interacts and Stabilizes HIF-2α via Binding to the HIF-2α bHLH and PAS Domains.
    Haque M; Kousoulas KG
    J Virol; 2019 Sep; 93(17):. PubMed ID: 31189709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 Inhibits Cellular IRF-5.
    Wies E; Hahn AS; Schmidt K; Viebahn C; Rohland N; Lux A; Schellhorn T; Holzer A; Jung JU; Neipel F
    J Biol Chem; 2009 Mar; 284(13):8525-38. PubMed ID: 19129183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Repurposing Cytarabine for Treating Primary Effusion Lymphoma by Targeting Kaposi's Sarcoma-Associated Herpesvirus Latent and Lytic Replications.
    Gruffaz M; Zhou S; Vasan K; Rushing T; Michael QL; Lu C; Jung JU; Gao SJ
    mBio; 2018 May; 9(3):. PubMed ID: 29739902
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The DNase Activity of Kaposi's Sarcoma-Associated Herpesvirus SOX Protein Serves an Important Role in Viral Genome Processing during Lytic Replication.
    Uppal T; Meyer D; Agarwal A; Verma SC
    J Virol; 2019 Apr; 93(8):. PubMed ID: 30728255
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genipin Enhances Kaposi's Sarcoma-Associated Herpesvirus Genome Maintenance.
    Cho M; Jung SW; Lee S; Son K; Park GH; Jung JW; Shin YS; Seo T; Hyosun Cho ; Kang H
    PLoS One; 2016; 11(10):e0163693. PubMed ID: 27736870
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Site-specific association with host and viral chromatin by Kaposi's sarcoma-associated herpesvirus LANA and its reversal during lytic reactivation.
    Mercier A; Arias C; Madrid AS; Holdorf MM; Ganem D
    J Virol; 2014 Jun; 88(12):6762-77. PubMed ID: 24696474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early activation of the Kaposi's sarcoma-associated herpesvirus RTA, RAP, and MTA promoters by the tetradecanoyl phorbol acetate-induced AP1 pathway.
    Wang SE; Wu FY; Chen H; Shamay M; Zheng Q; Hayward GS
    J Virol; 2004 Apr; 78(8):4248-67. PubMed ID: 15047839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.